DZD9008+AZD4205

Phase 2Small molecule

DDizal Pharmaceuticals

DZD9008+AZD4205 is one of 2 small molecule programs targeting Phase II Clinical Trial. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase II Clinical TrialRecruiting

Phase II Clinical TrialPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Phase II Clinical Trial

#DrugCompanyPhaseTrials

Carbon Nanoparticle-Loaded Iron

SSichuan Enray Pharmaceutical Sciences Company

Phase 2

1 2

DZD9008+AZD4205

DDizal Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Phase II Clinical Trial

NCT06295432

Clinical

Trials by Indication[1]

Phase II Clinical Trial1 trial

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Recruiting·DDizal Pharmaceuticals·Phase 2·NCT06295432·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DZD9008+AZD4205. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DZD9008+AZD4205 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DZD9008+AZD4205. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dizal Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDizal Pharmaceuticals

DZD9008+AZD4205

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Phase II Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News